Drug Trial Radar · NCT07053215
Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC
Last checked: Nov 19, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Dec 1, 2020
Primary completion
Dec 1, 2024
Study completion Dec 1, 2024
Sponsor
- Lead sponsor
- The First Hospital of Hebei Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 8, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized controlled trial investigated the efficacy and safety of argon-helium cryoablation combined with PD-1 inhibitors compared to PD-1 inhibitors plus chemotherapy for treating non-small cell lung cancer (NSCLC). The study aimed to evaluate differences in survival, tumor response, immune function, and adverse events.
Conditions
- Non-small Cell Lung Cancer (NSCLC)
Interventions
Argon-Helium CryoablationDevice
Procedure performed within 7 days before the first dose of PD-1 inhibitor. CT-guided insertion of cryoprobes into the target tumor. Two freeze-thaw cycles: rapid freeze to -135°C to -145°C for 15-20 minutes, followed by thawing.
CamrelizumabDrug
200 mg intravenously every 3 weeks for 4 cycles.
Platinum-based doublet chemotherapyDrug
* Non-squamous NSCLC: Pemetrexed (500 mg/m² IV on day 1) plus Carboplatin (AUC 5 mg/mL•min IV on day 1) of each 3-week cycle. * Squamous NSCLC: Gemcitabine (1250 mg/m² IV on days 1 and 8) plus Carboplatin (AUC 5 mg/mL•min IV on day 1) of each 3-week cycle. * Administered for 4 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From randomization until death, assessed through study completion, an average of 1 year.
- Progression-Free Survival (PFS)Time frame: From randomization until disease progression or death, assessed through study completion, an average of 1 year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
the First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.